Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.31 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.31 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3074353 | 0.83 | SLC5A2 (0.34) | SLC5A2SLC5A1KCNN2KCNN3 | |
| SCHEMBL3089243 | 0.83 | LTA4H (0.46) | TP53 | |
| SCHEMBL3097520 | 0.83 | SLC6A4 (0.49) | CYP1A2SLC5A2SLC5A1 | |
| SCHEMBL458549 | 0.82 | GABRA1 (0.41) | CYP1A2GABRA1GABRB2 | |
| SCHEMBL3087655 | 0.75 | TLR8 (0.33) | TP53SLC5A2SLC5A1 | |
| SCHEMBL5141784 | 0.75 | GRM5 (0.33) | GABRA1GABRB2 | |
| SCHEMBL2257083 | 0.72 | TLR8 (0.38) | — | |
| SCHEMBL27838122 | 0.72 | CYP2C19 (0.49) | CYP1A2CYP2A6 | |
| SCHEMBL9227837 | 0.71 | — | — | |
| SCHEMBL2251931 | 0.70 | LIPG (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207134-B2 | Fused ring spiroketal derivative and use thereof as anti-diabetic drug | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20100234609-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-09-16 | — | — | US | disclosed |
| CN-101495494-A | Fused ring spiroketal derivative and use thereof as therapeutic agent for diabetes | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-07-29 | — | — | CN | disclosed |
| EP-2048152-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234609-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG | REN, WNK1, GCKR | CYP1A2 1128/4885CYP2A6 79/4885TP53 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.